SOD1 and endothelial dysfunction: Like the effects of lovastatin in diabetes, lovastatin also eliminated all HTL-induced harmful effects in dose-dependent manner, including reduction of acetylcholine-induced vasorelaxation (Figure 7D), enhancement of serum MDA level (Figure 7E), and decreased activities of SOD and GSH-Px (Figure 7F and Figure 7G) in blood from rats fed with HTL, further supporting that prevention of endothelial dysfunction by lovastatin is a common mechanism to prevent or treat CVD induced by multiple cardiovascular risk factors.